Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin

Sponsor
Medical University Innsbruck (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT01895725
Collaborator
(none)
443
1
175
2.5

Study Details

Study Description

Brief Summary

The proposed project is a prospective observational, single-center cohort study aimed to examine the progression of atherosclerotic alterations of the carotid arteries (IMT, plaque volume) during a follow-up of up to four years and to correlate the observed changes with traditional and novel biomarkers of atherosclerosis. A total of 600 subsequent patients with or established cardiovascular disease or at least one cardiovascular risk will be tested with a high-frequency ultrasound probe equipped with automated IMT measurements and 3D quantitative plaque volumetry. Plasma samples will be collected and tested for traditional and novel cardiovascular risk factors. Both ultrasound examinations and blood sampling will be repeated once per year to assess changes in these parameters over time depending on treatment modalities, which are left to the discretion of the treating physicians. The primary endpoint of the planned study will be the correlation between P-selectin and the progression of atherosclerosis as measured by plaque volume and IMT in the carotid and femoral arteries, respectively. Secondary endpoints will include the correlation of established (hypertension, smoking, diabetes, dyslipidemia) and novel risk factors (hsCRP, P-selectin, cholesteryl ester transfer protein (CETP), intercellular adhesion molecule-1 (ICAM-1), CETP TaqIb polymorphism) with the progression of atherosclerosis, the correlation of cardiovascular events with the progression of atherosclerosis and the additional predictive value of plaque volume and IMT compared to an established risk score (SCORE card).

Study Design

Study Type:
Observational
Actual Enrollment :
443 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin
Study Start Date :
Jun 1, 2013
Actual Primary Completion Date :
Jan 30, 2020
Anticipated Study Completion Date :
Jan 1, 2028

Outcome Measures

Primary Outcome Measures

  1. Correlation between P-selectin and the progression of atherosclerosis [up to 4 years]

    The primary endpoint of the planned study will be the correlation between P-selectin and the progression of atherosclerosis as measured by plaque volume and IMT in the carotid and femoral arteries

Secondary Outcome Measures

  1. Correlation of cardiovascular events with the progression of atherosclerosis [up to 4 years]

    As secondary endpoints, cardiovascular events (cardiovascular death, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), coronary bypass surgery, stroke, transient ischemic attack (TIA), surgery for aortic aneurysm, critical limb ischemia, peripheral percutaneous transluminal angioplasty (PTA), peripheral bypass) will be correlated with the progression of atherosclerosis and the additional predictive value of plaque volume and IMT in carotid and or femoral arteries compared to an established clinical risk score risk score (SCORE card) will be calculated

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients (male and female) aged 30 to 85 years

  • with at least one traditional cardiovascular risk factor (hypertension, smoking, diabetes, dyslipidemia, family history) or established coronary artery disease, cerebrovascular disease, or peripheral artery disease diagnosed by objective testing

Exclusion Criteria:
  • lack of informed consent

  • the impossibility of follow-up testing once per year for the following four years

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University Innsbruck, Department for Internal Medicine III Innsbruck Austria 6020

Sponsors and Collaborators

  • Medical University Innsbruck

Investigators

  • Principal Investigator: Peter Marschang, MD, Medical University Innsbruck

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peter Marschang, Prof. MD, Medical University Innsbruck
ClinicalTrials.gov Identifier:
NCT01895725
Other Study ID Numbers:
  • P-selectin 03-13
First Posted:
Jul 10, 2013
Last Update Posted:
May 14, 2021
Last Verified:
May 1, 2021

Study Results

No Results Posted as of May 14, 2021